Search research articles
Contact Us
Filters
Showing results (291-300 of 418) with videos related to
Page
of 42
Sort By:
European Urology Focus
|
February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
Peter E Hall, Scott T C Shepherd, Janet Brown, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Kidney Journal
|
June 3, 2026
Environmental footprint of peritoneal dialysis in Europe: a comparative life cycle assessment across four European centres
Abass Fehintola, Zuzanna Jakubowska, Malgorzata Kepska-Dzilinska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Hepatology
|
February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Page
of 42
Search research articles
Search
Showing results (291-300 of 418) with videos related to
Sort By:
Page
of 42
European Urology Focus
|
February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
Peter E Hall, Scott T C Shepherd, Janet Brown, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Kidney Journal
|
June 3, 2026
Environmental footprint of peritoneal dialysis in Europe: a comparative life cycle assessment across four European centres
Abass Fehintola, Zuzanna Jakubowska, Malgorzata Kepska-Dzilinska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Hepatology
|
February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Page
of 42